Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALVAC-HIV and Bivalent Subtype C gp120/MF59 in Preventing HIV-1 Infection in Adults in South Africa
NCT02968849Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2016
- Primary completion
- Nov 2021
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing ALVAC-HIV + subtype C gp120/MF59 with Placebo (2 arms). Primary endpoints: Incidence Rate of HIV-1 Infection Diagnosed After Enrollment at 36 months, Number of Participants Reporting Local Reactogenicity Signs and Symptoms and 4 more. Started Oct 2016; status: completed.
02
Drugs
ALVAC-HIVbivalent subtype C gp120/MF59
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02968849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02968849.